Literature DB >> 22977394

Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis.

.   

Abstract

Entities:  

Year:  2010        PMID： 22977394      PMCID： PMC3411137     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN： 1203-9012


× No keyword cloud information.
  7 in total

1.  Responsible use of blood products in response to supply and demand.

Authors:  K Colgan; M L Moody; K Witte
Journal:  Am J Health Syst Pharm       Date:  2000-11-15       Impact factor: 2.637

Review 2.  Pathogen inactivation of labile blood products.

Authors: 
Journal:  Transfus Med       Date:  2001-06       Impact factor: 2.019

Review 3.  Reducing the risk of infection from plasma products: specific preventative strategies.

Authors:  T Burnouf; M Radosevich
Journal:  Blood Rev       Date:  2000-06       Impact factor: 8.250

4.  Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply.

Authors:  J P AuBuchon; J D Birkmeyer
Journal:  JAMA       Date:  1994-10-19       Impact factor: 56.272

5.  Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma.

Authors:  A Pereira
Journal:  Transfusion       Date:  1999-05       Impact factor: 3.157

6.  Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

Authors:  G F Riedler; A R Haycox; A K Duggan; H A Dakin
Journal:  Vox Sang       Date:  2003-08       Impact factor: 2.144

Review 7.  Modern plasma fractionation.

Authors:  Thierry Burnouf
Journal:  Transfus Med Rev       Date:  2007-04
  7 in total
  15 in total

1.  A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

Authors:  John-Michael Gamble; Dean T Eurich; Jeffrey A Johnson
Journal:  Healthc Policy       Date:  2010-11

2.  Listening for prescriptions: a national consultation on pharmaceutical policy issues.

Authors:  Steve Morgan; Colleen M Cunningham
Journal:  Healthc Policy       Date:  2010-11

3.  American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Giuseppe Giaccone; Sarah Temin
Journal:  J Oncol Pract       Date:  2010-01       Impact factor: 3.840

Review 4.  Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply.

Authors:  Andrew D Johnson; Claudia S Cohn
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

5.  The Role of Pharmacists and Pharmacy Education in Point-of-Care Testing.

Authors:  James P Kehrer; Deborah E James
Journal:  Am J Pharm Educ       Date:  2016-10-25       Impact factor: 2.047

6.  Budget impact analysis of osteoporosis medications for primary prevention of fractures in Taiwan.

Authors:  Kun-Ling Wu; Chih-Hsing Wu; Yin-Fan Chang; Yun-Ting Lin; Jason C Hsu
Journal:  J Bone Miner Metab       Date:  2019-11-11       Impact factor: 2.626

7.  Knowledge Transfer within the Canadian Chiropractic Community. Part 2: Narrowing the Evidence-Practice Gap.

Authors:  Greg Kawchuk; Genevieve Newton; John Srbely; Steven Passmore; André Bussières; Jason W Busse; Paul Bruno
Journal:  J Can Chiropr Assoc       Date:  2014-09

Review 8.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

9.  Impact of impairment and secondary health conditions on health preference among Canadians with chronic spinal cord injury.

Authors:  Catharine Craven; Sander L Hitzig; Nicole Mittmann
Journal:  J Spinal Cord Med       Date:  2012-09       Impact factor: 1.985

10.  Measuring low-value care in Medicare.

Authors:  Aaron L Schwartz; Bruce E Landon; Adam G Elshaug; Michael E Chernew; J Michael McWilliams
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.